Santos-Sánchez Norma Francenia, Salas-Coronado Raúl
Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. ORCID: 0000-0001-5094-0488.
Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. Dirección: km 2,5 Huajuapan de León, Oaxaca, México, Código postal: 69000. Email:
Medwave. 2020 Sep 25;20(8):e8037. doi: 10.5867/medwave.2020.08.8037.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected with COVID-19 shows varying manifestations, depending on their health and age. The most common symptoms are fever, cough, myalgia, fatigue, odynophagia, and dyspnea. Infected adults older 60 years of age are the group of patients most susceptible to severe COVID-19 states and present comor-bidity in the presence of chronic diseases. On the other hand, it is also essential to have tests to detect SARS-COV-2 in people and follow the evolution of COVID-19 quickly, reliably, and cheap. To achieve this, there are real-time reverse transcription pol-ymerase chain reaction (RT-PCR) tests, isothermal nucleic acid amplification, and enzyme immunostimulation. Currently, there are no drug treatments to prevent infection and to combat the virus's effects. However, different research groups that are conduct-ing in vitro, in vivo, and in silico tests to find drugs able to provide an immune response and to control infection in humans with SARS-CoV-2. Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19. The purpose of this review is to establish a reference framework for taxonomic classification of SARS-CoV-2 and the relationship they have with other CoVs, as well as their structure and propaga-tion pathways in humans. The characteristics and symptoms presented by patients with COVID-19, the detection methods, and possible treatments are also presented.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发2019冠状病毒病(COVID-19)。2019年12月在中国武汉市发现了这种疾病。感染COVID-19的人表现出不同的症状,这取决于他们的健康状况和年龄。最常见的症状是发热、咳嗽、肌痛、疲劳、吞咽痛和呼吸困难。60岁以上的感染成年人是最易患严重COVID-19状态的患者群体,并且在患有慢性病时会出现合并症。另一方面,进行检测以在人群中检测SARS-CoV-2并快速、可靠且廉价地跟踪COVID-19的演变情况也很重要。为此,有实时逆转录聚合酶链反应(RT-PCR)检测、等温核酸扩增和酶免疫刺激检测。目前,尚无预防感染和对抗病毒作用的药物治疗方法。然而,不同的研究小组正在进行体外、体内和计算机模拟试验,以寻找能够提供免疫反应并控制人类感染SARS-CoV-2的药物。氯喹、羟氯喹、瑞德西韦、干扰素α2b和奥司他韦是在预防COVID-19的临床试验中评估的一些药理学选择。本综述的目的是建立一个参考框架,用于SARS-CoV-2的分类学分类及其与其他冠状病毒的关系,以及它们在人体内的结构和传播途径。还介绍了COVID-19患者呈现的特征和症状、检测方法以及可能的治疗方法。